Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.

Mahanjit Konwar Debdipta Bose Sanjeet Kumar Jaiswal Mitesh Kumar Maurya Renju Ravi

Published in: International journal of clinical practice (2022)

Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.

Keyphrases

weight loss
weight gain
type diabetes
glycemic control
body mass index
physical activity
cardiovascular disease
insulin resistance
metabolic syndrome
wound healing
double blind
skeletal muscle
placebo controlled
study protocol